Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 2
2006 2
2007 2
2010 3
2011 9
2012 9
2013 7
2014 14
2015 17
2016 19
2017 15
2018 16
2019 23
2020 20
2021 28
2022 20
2023 14
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Results by year

Filters applied: . Clear all
Page 1
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
Yonesaka K, Tanizaki J, Maenishi O, Haratani K, Kawakami H, Tanaka K, Hayashi H, Sakai K, Chiba Y, Tsuya A, Goto H, Otsuka E, Okida H, Kobayashi M, Yoshimoto R, Funabashi M, Hashimoto Y, Hirotani K, Kagari T, Nishio K, Nakagawa K. Yonesaka K, et al. Among authors: sakai k. Clin Cancer Res. 2022 Jan 15;28(2):390-403. doi: 10.1158/1078-0432.CCR-21-3359. Epub 2021 Dec 17. Clin Cancer Res. 2022. PMID: 34921025
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: sakai k. J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25. J Thorac Oncol. 2023. PMID: 37364849
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, Goto M, Chiba Y, Tomida S, Ota T, Haratani K, Takahama T, Tanizaki J, Yoshida T, Iwasa T, Tanaka K, Takeda M, Hirano T, Yoshida H, Ozasa H, Sakamori Y, Sakai K, Higuchi K, Uga H, Suminaka C, Hirai T, Nishio K, Nakagawa K, Honjo T. Hayashi H, et al. Among authors: sakai k. J Clin Invest. 2024 Apr 1;134(7):e168318. doi: 10.1172/JCI168318. J Clin Invest. 2024. PMID: 38557498 Free PMC article.
Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer.
Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I. Tanaka K, et al. Among authors: sakai k. Sci Transl Med. 2022 Dec 14;14(675):eabq0021. doi: 10.1126/scitranslmed.abq0021. Epub 2022 Dec 14. Sci Transl Med. 2022. PMID: 36516270
New Era for Next-Generation Sequencing in Japan.
Takeda M, Sakai K, Takahama T, Fukuoka K, Nakagawa K, Nishio K. Takeda M, et al. Among authors: sakai k. Cancers (Basel). 2019 May 28;11(6):742. doi: 10.3390/cancers11060742. Cancers (Basel). 2019. PMID: 31142054 Free PMC article. Review.
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K. Hayashi H, et al. Among authors: sakai k. Clin Cancer Res. 2022 Mar 1;28(5):893-902. doi: 10.1158/1078-0432.CCR-21-3194. Clin Cancer Res. 2022. PMID: 34921023 Free PMC article. Clinical Trial.
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, Kato S, Maenishi O, Sakai K, Chiba Y, Okabe T, Kudo K, Hasegawa Y, Kaneda H, Yamato M, Hirotani K, Miyazawa M, Nishio K, Nakagawa K. Yonesaka K, et al. Among authors: sakai k. Clin Cancer Res. 2018 Jun 1;24(11):2653-2664. doi: 10.1158/1078-0432.CCR-17-2852. Epub 2018 Mar 12. Clin Cancer Res. 2018. PMID: 29530936
199 results